The U.S. Food and Drug Administration has granted approval for Moderna's innovative mRNA-based influenza vaccine, marking a significant advancement in seasonal flu prevention. This pivotal decision follows an initial refusal by the regulatory agency to review the application, a stance that triggered considerable public disapproval. The FDA subsequently reversed its position, driven by the widespread outcry, leading to a comprehensive review and ultimately, the vaccine's green light for public use.
